Verghese Valsan Philip, Veeraraghavan Balaji, Jayaraman Ranjith, Varghese Rosemol, Neeravi Ayyanraj, Jayaraman Yuvaraj, Thomas Kurien, Mehendale Sanjay M
Department of Paediatrics, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Department of Clinical Microbiology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Indian J Med Microbiol. 2017 Apr-Jun;35(2):228-236. doi: 10.4103/ijmm.IJMM_17_124.
Pneumococcal meningitis is a life-threatening infection, requiring prompt diagnosis and effective treatment. Penicillin resistance in pneumococcal infections is a concern. Here, we present the antibiotic susceptibility profile of pneumococcal meningeal isolates from January 2008 to August 2016 to elucidate treatment guidelines for pneumococcal meningitis.
Invasive pneumococcal isolates from all age groups, were included in this study. Minimum inhibitory concentrations for the isolates were identified by agar dilution technique and VITEK System 2. Serotyping of isolates was done by co-agglutination technique.
Out of 830 invasive pneumococcal isolates, 167 (20.1%) isolates were from meningeal infections. Cumulative penicillin resistance in pneumococcal meningitis was 43.7% and cefotaxime non-susceptibility was 14.9%. Penicillin resistance amongst meningeal isolates in those younger than 5 years, 5-16 years of age and those aged 16 years and older was 59.7%, 50% and 27.3%, respectively, with non-susceptibility to cefotaxime in the same age groups being 18%, 22.2% and 10.4%. Penicillin resistance amongst pneumococcal meningeal isolates increased from 9.5% in 2008 to 42.8% in 2016, whereas cefotaxime non-susceptibility increased from 4.7% in 2008 to 28.5% in 2016. Serotypes 14, 19F, 6B, 6A, 23F, 9V and 5 were the most common serotypes causing meningitis, with the first five accounting for over 75% of resistant isolates.
The present study reports increasing penicillin resistance and cefotaxime non-susceptibility to pneumococcal meningitis in our setting. This highlights the need for empiric therapy with third-generation cephalosporins and vancomycin for all patients with meningitis while awaiting results of culture and susceptibility testing.
肺炎球菌性脑膜炎是一种危及生命的感染,需要及时诊断和有效治疗。肺炎球菌感染中的青霉素耐药性是一个令人担忧的问题。在此,我们展示2008年1月至2016年8月肺炎球菌性脑膜炎分离株的抗生素敏感性概况,以阐明肺炎球菌性脑膜炎的治疗指南。
本研究纳入了所有年龄组的侵袭性肺炎球菌分离株。通过琼脂稀释技术和VITEK 2系统确定分离株的最低抑菌浓度。分离株的血清分型采用协同凝集技术。
在830株侵袭性肺炎球菌分离株中,167株(20.1%)来自脑膜感染。肺炎球菌性脑膜炎中青霉素的累积耐药率为43.7%,头孢噻肟不敏感率为14.9%。5岁以下、5至16岁以及16岁及以上的脑膜分离株中,青霉素耐药率分别为59.7%、50%和27.3%,同一年龄组中头孢噻肟不敏感率分别为18%、22.2%和10.4%。肺炎球菌性脑膜分离株中的青霉素耐药率从2008年的9.5%增至2016年的42.8%,而头孢噻肟不敏感率从2008年的4.7%增至2016年的28.5%。14型、19F型、6B型、6A型、23F型、9V型和5型是引起脑膜炎最常见的血清型,前五种血清型占耐药分离株的75%以上。
本研究报告了在我们的研究环境中,肺炎球菌性脑膜炎对青霉素的耐药性和对头孢噻肟的不敏感性不断增加。这突出表明,在等待培养和药敏试验结果期间,所有脑膜炎患者都需要使用第三代头孢菌素和万古霉素进行经验性治疗。